ADMA Biologics, Inc.’s share price was $17.80 on August 22nd. The company has shown a financial turnaround, with gross profit growing at a 34% CAGR from 2020 to 2024. Net income went from a loss of $75.5 million in 2020 to profitability of $197.7 million in 2024.

The company’s margins have strengthened, with return on invested capital reaching 78%. ADMA’s founders are actively involved, despite insider ownership being at 2%. Valuation metrics indicate undervaluation, with forward P/E and P/FCF below historical medians. The company has initiated buybacks in 2024, showing confidence in future performance.

Bio-Techne Corporation (TECH) faced a 19.11% stock price depreciation since May 2025. Despite this, the bullish thesis on ADMA Biologics focuses on profitability inflection and undervaluation, with a similar stance to the one taken on TECH. ADMA’s organic growth rebound and strong financial performance make it an attractive investment opportunity.

Read more at Yahoo Finance: ADMA Biologics, Inc. (ADMA): A Bull Case Theory